P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL. (23rd June 2022) - Mai, E. K.; Bertsch, U.; Fenk, R.; Tichy, D.; Besemer, B.; Dürig, J.; Schroers, R.; von Metzler, I.; Hänel, M.; Mann, C.; Asemissen, A. M.; Heilmeier, B.; et al.